
FDA clears Waters' at-home HPV screening to speed cervical cancer detection
The U.S. FDA has cleared Waters’ at-home cervical cancer screening kit for use with an approved HPV test, enabling patients to self-collect samples at home and mail them to a laboratory. The kit, tested with BD’s Onclarity HPV assay, targets high-risk HPV types and aims to improve early detection and reduce cervical cancer deaths, with Waters planning nationwide availability by prescription and anticipated insurance coverage.

